

**APOC3 Antibody (C-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP7797b****Specification**

---

**APOC3 Antibody (C-term) Blocking Peptide - Product Information**Primary Accession [P02656](#)**APOC3 Antibody (C-term) Blocking Peptide - Additional Information****Gene ID** 345**Other Names**

Apolipoprotein C-III, Apo-CIII, ApoC-III, Apolipoprotein C3, APOC3

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7797b](/products/AP7797b) was selected from the C-term region of human APOC3. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**APOC3 Antibody (C-term) Blocking Peptide - Protein Information****Name** APOC3**Function**

Component of triglyceride-rich very low density lipoproteins (VLDL) and high density lipoproteins (HDL) in plasma (PubMed:[18201179](http://www.uniprot.org/citations/18201179), PubMed:[22510806](http://www.uniprot.org/citations/22510806)). Plays a multifaceted role in triglyceride homeostasis (PubMed:[18201179](http://www.uniprot.org/citations/18201179), PubMed:[22510806](http://www.uniprot.org/citations/22510806)). Intracellularly, promotes hepatic very low density lipoprotein 1 (VLDL1) assembly and secretion; extracellularly, attenuates hydrolysis and clearance of triglyceride-rich lipoproteins (TRLs) (PubMed:[18201179](http://www.uniprot.org/citations/18201179), PubMed:[22510806](http://www.uniprot.org/citations/22510806)). Impairs the lipolysis of TRLs by inhibiting lipoprotein lipase and the hepatic uptake of TRLs by remnant receptors (PubMed:[18201179](http://www.uniprot.org/citations/18201179))

target="\_blank">18201179</a>, PubMed:<a href="http://www.uniprot.org/citations/22510806" target="\_blank">22510806</a>). Formed of several curved helices connected via semiflexible hinges, so that it can wrap tightly around the curved micelle surface and easily adapt to the different diameters of its natural binding partners (PubMed:<a href="http://www.uniprot.org/citations/18408013" target="\_blank">18408013</a>).

**Cellular Location**

Secreted

**Tissue Location**

Liver..

**APOC3 Antibody (C-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**APOC3 Antibody (C-term) Blocking Peptide - Images****APOC3 Antibody (C-term) Blocking Peptide - Background**

Apolipoprotein C-III is a very low density lipoprotein (VLDL) protein. APOC3 inhibits lipoprotein lipase and hepatic lipase; it is thought to delay catabolism of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.

**APOC3 Antibody (C-term) Blocking Peptide - References**

Liu,Y., Pharmacogenet. Genomics 19 (2), 161-169 (2009)Pollin,T.I., Science 322 (5908), 1702-1705 (2008)